Sintilimab as adjuvant therapy for high-risk hepatocellular carcinoma after curative resection: a multicentric retrospective cohort study
These findings support the potential of 6 months sintilimab monotherapy or in combination with TKIs as an effective adjuvant therapy for patients with HCC at high risk of recurrence. Further large-scale randomized controlled trials should be warranted.
Authors
- Li-Xin Pan (ORCID: https://orcid.org/0000-0002-3491-5095)
- Shuchang Chen (ORCID: https://orcid.org/0000-0001-8374-2672)
- C. Chen
- Wenxuan Liu (ORCID: https://orcid.org/0000-0003-1227-0991)
- Jianbo Shao (ORCID: https://orcid.org/0000-0002-8424-8921)
- Jia‐Yong Su (ORCID: https://orcid.org/0000-0002-0960-5394)
- Dalong Yang (ORCID: https://orcid.org/0000-0003-0090-2277)
- Ze Su (ORCID: https://orcid.org/0009-0000-1360-0783)
- Jian‐Hong Zhong (ORCID: https://orcid.org/0000-0002-1494-6396)
- Ning Peng (ORCID: https://orcid.org/0000-0003-4213-1159)
- Xiaoling Xu (ORCID: https://orcid.org/0009-0002-8258-7935)
- Rong‐Rui Huo (ORCID: https://orcid.org/0000-0002-3723-9619)
- Shaoping Liu
- Liang Ma (ORCID: https://orcid.org/0009-0008-2312-5750)
- Xuan He (ORCID: https://orcid.org/0000-0003-3547-2801)
- Pingping Guo (ORCID: https://orcid.org/0000-0002-0371-1460)
- Zhu‐Jian Deng
- Jun‐Jie Ou (ORCID: https://orcid.org/0009-0003-2700-1118)
- Yi-Li Ma
- Yi Zhang (ORCID: https://orcid.org/0000-0001-6223-4724)
Institutions
- Guangxi Medical University (CN)
- Wuzhou University (CN)
- Guigang City People's Hospital (CN)
- First Affiliated Hospital of GuangXi Medical University (CN)
- First People's Hospital of Nanning (CN)
Publication Details
- Journal
- European Journal of Gastroenterology & Hepatology
- Published
- 2025-11-26
- DOI
- https://doi.org/10.1097/meg.0000000000003080
- Primary Topic
- Hepatocellular Carcinoma Treatment and Prognosis
- Type
- article
- Field-Weighted Citation Impact
- 0.00